No Data
No Data
Buy Rating Affirmed: Taysha Gene Therapies Poised for Breakthrough on Pediatric Data and FDA Support
Analysts Offer Insights on Healthcare Companies: Sutro Biopharma (STRO), Athira Pharma (ATHA) and Taysha Gene Therapies (TSHA)
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Biogen (BIIB)
Cantor Fitzgerald Company: The Taysha Gene Therapies (TSHA.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.
Cantor Fitzgerald Company: The Taysha Gene Therapies (TSHA.US) rating was reaffirmed and adjusted from an increase to an increase in holdings rating, with a target price of $7.00.
Truist Financial Reaffirms Their Buy Rating on Taysha Gene Therapies (TSHA)
Taysha Gene Therapies (TSHA) Gets a Buy From Cantor Fitzgerald